Understanding the spectrum of malignant bowel obstructions in gynecologic cancers and the application of the Henry score

• Published in: Gynecologic oncology 2023-07, Vol.174, p.114-120
• Main Authors: Moyett, Julia M., Howell, Elizabeth P., Broadwater, Gloria, Greene, Melissa, Secord, Angeles Alvarez, Watson, Catherine H., Davidson, Brittany A.
• Format: Article
• Language: English
• Subjects: Bowel obstruction; Gynecologic cancer; Henry score; Prognosis
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2023.04.023

Malignancy-associated bowel obstruction (MBO) is a potential sequela of advanced gynecologic cancers, adversely impacting both quality of life and prognosis. The Henry score (HS) was developed in a gastrointestinal cancer-predominant population to predict 30-day mortality. We aim to characterize MBO in gynecologic cancers and assess the utility of the HS in this population. This is a retrospective review of patients with gynecologic cancer and MBO admitted to a single academic institution from 2016 to 2021. The primary outcome is to characterize malignant small and large bowel obstructions in primary and recurrent gynecologic cancer using readmission and mortality rates. Secondary outcomes are to assess the Henry score and inpatient MBO management. 179 patients totaling 269 were admissions identified, most commonly affecting patients with ovarian cancer. The majority (89.4%) were managed non-operatively while 10.6% were managed surgically. No significant differences were observed in survival for medical versus surgical management. Thirty-day mortality increased with increasing HS (0%, 0–1; 14.3%, 2–3; 40.9%, 4–5). Over 1/3 (34.1%) of patients were readmitted for recurrent or persistent MBO. Goals of care conversations were documented for 56.8% of patients with HS 4–5. Mortality rates across the entire cohort were high—20.1% and 60.9% had died by 1 and 6 months, respectively. Survival rates following an initial MBO admission are poor. The HS has utility in gynecologic cancers for assessing 30-day mortality and may be a useful tool to aid in the management and counseling of patients with gynecologic cancer and MBO. •Higher Henry scores were associated with increased 30-day mortality for this cohort of solely gynecologic cancer patients•There was no statistically significant difference in overall survival for surgical versus medical management of MBO•Median survival was poor for patients with MBO during first line treatment and in the recurrent cancer setting